Pharmaceutical development for oxfendazole

[Published: 22 November, 2016]
DNDi is seeking a CDMO offering an integrated platform of pharmaceutical development and manufacturing capabilities to cover drug substance and drug product activities.

Data management, biostatistic and monitoring services

[Published: 11 May, 2016]
DNDi would like to conduct an open label phase II/III multicenter, trial to assess the efficacy, safety, tolerance and pharmacokinetics of sofosbuvir plus ravidasvir in HCV (+/- HIV) chronically infected adults with no or compensated cirrhosis in Thailand and Malaysia.

DNDi is looking for a CRO able to perform Data Management, Biostatistic and Monitoring Services.